A plain-language, continually updated guide from Dr. Matt Chalmers’ clinical reference on hormones and peptides.
Tirzepatide is a dual receptor agonist — it activates both the GLP-1 receptor (like Semaglutide) and the GIP receptor, a second incretin pathway that Semaglutide doesn’t touch. That second pathway is what sets it apart: GIP receptor activation directly improves insulin sensitivity in fat and muscle tissue, something GLP-1 alone doesn’t accomplish. It’s approved as Mounjaro for type 2 diabetes (2022) and Zepbound for chronic weight management (2023).
In head-to-head data, Tirzepatide has outperformed Semaglutide on several measures: roughly 20.9% average weight loss at 72 weeks (SURMOUNT-1) versus roughly 15% for Semaglutide (STEP-1) at a similar timeframe, greater visceral fat reduction, and notably less nausea (about 33% vs. 44%) — the added GIP signaling appears to partially offset the nausea-triggering effect of GLP-1 activation alone.
One clinically important detail that’s easy to get wrong: if you’re switching from Semaglutide to Tirzepatide, treatment should always restart at the lowest dose (2.5 mg), regardless of what dose of Semaglutide you were previously on. Tirzepatide’s dual mechanism creates a different tolerability profile, and skipping this reset is one of the most commonly made mistakes in GLP-1 therapy. Worth knowing too: lean-mass loss tends to be more significant with Tirzepatide than Semaglutide in trial data, which is exactly why protein intake and resistance training are built into how our providers manage this therapy, not treated as optional.
Because this pathway reduces food intake, maintaining adequate protein and overall micronutrient intake (including B12, iron, and zinc) is an important part of supporting the body through the process — reduced intake without attention to nutrient density can compound deficiency risk, and this matters even more for Tirzepatide given its more pronounced lean-mass effect.
Tirzepatide is FDA-approved for specific indications under brand names such as Mounjaro® and Zepbound®. Use outside an approved indication is considered off-label and is determined individually by your provider.
Yes — both are FDA-approved specifically for chronic weight management (in addition to type 2 diabetes), and the clinical trials supporting those approvals documented significant average weight loss in study participants. This is the approved, on-label use of these medications. Individual results vary, and appropriateness is determined through an individualized evaluation with our providers.
In head-to-head trial data, Tirzepatide has produced greater average weight loss and less nausea than Semaglutide, attributed to its added GIP receptor activity. “Better” still depends on your individual health picture, tolerability, and goals — which is why our providers make this determination case by case rather than defaulting to one option.
Tirzepatide may be included as part of our Metabolic Reset program, which addresses insulin resistance, sleep, and hormones together.
This page draws on The Pillars Path: A Root-Cause Guide to Hormones, Peptides, and Metabolic Health by Dr. Matt Chalmers — Pillars of Wellness’ clinical reference on hormone and peptide therapy.
